Published in J Immunol Methods on November 06, 1986
The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A (1991) 3.40
Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci U S A (1988) 3.04
Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A (1990) 2.88
Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A (1992) 2.73
Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med (1990) 2.62
Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha. Proc Natl Acad Sci U S A (1990) 2.37
Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci U S A (1990) 2.13
Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents. J Clin Invest (1987) 1.26
Tumor necrosis factor alpha-induced pulmonary vascular endothelial injury. Infect Immun (1989) 1.25
Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5). J Exp Med (1988) 1.16
Induction of human IgE synthesis by CD4+ T cell clones. Requirement for interleukin 4 and low molecular weight B cell growth factor. J Exp Med (1989) 1.14
Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer (1999) 1.06
Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol (1993) 0.93
The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. Transplantation (1992) 0.91
Fungal beta-glucan interacts with vitronectin and stimulates tumor necrosis factor alpha release from macrophages. Infect Immun (1996) 0.87
Increased tumour necrosis factor alpha production by neutrophils in patients with hepatitis B. J Clin Pathol (1994) 0.87
Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer (2000) 0.80
In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. Br J Cancer (1999) 0.79
Progressive growth of human papillomavirus type 16-transformed keratinocytes is associated with an increased release of soluble tumour necrosis factor (TNF) receptor. Br J Cancer (1996) 0.76
Weight loss in obese mice persistently infected with lymphocytic choriomeningitis virus is not associated with elevated tumor necrosis factor/cachectin activity in peritoneal macrophages. Am J Pathol (1988) 0.76
Biological activity of mutants of human tumour necrosis factor-alpha. Immunology (1992) 0.75
Improvement of a cytokine (TNF-α) bioassay by serum-free target cell (WEHI 164) cultivation. Cytotechnology (1999) 0.75
A novel 96-well scintillation proximity assay for the measurement of apoptosis. Cytotechnology (1999) 0.75
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science (1984) 15.82
Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A (1992) 6.61
Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol (1979) 1.95
Plasma creatinine and urea: creatinine ratio in patients with raised plasma urea. Br Med J (1977) 1.59
Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol (1987) 1.49
High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology (N Y) (1992) 1.43
Maternal nutrition in early pregnancy. Br J Nutr (1977) 1.26
Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am J Med (1983) 1.13
The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Response Mod (1990) 1.07
Discriminant analysis of data in enzyme immunoassay. J Immunol Methods (1983) 1.04
Detection of IgG antibodies to measles virus using monoclonal antibodies for antigen-capture in enzyme immunoassay. J Virol Methods (1984) 1.00
Effect of IFN-gamma on the killing of S. aureus in human whole blood. Assessment of bacterial viability by CFU determination and by a new method using alamarBlue. J Immunol Methods (2000) 0.89
Interferon gamma administration increases monocyte HLA-DR antigen expression but not endogenous interferon production. Arch Surg (1994) 0.87
Comparison of TNF-alpha and TNF-beta cytolytic biological activities in a serum-free bioassay. Lymphokine Res (1986) 0.81
Enzyme-linked bio-immunoassay for IFN-gamma by HLA-DR induction. J Immunol Methods (1989) 0.78
Biological activity of a monoclonal antibody to a measles virus haemagglutinin epitope detected late in infection. J Gen Virol (1984) 0.77
Modulation of leukocyte cyclic AMP phosphodiesterase activity by recombinant interferon-gamma: evidence for a differential effect on atopic monocytes. J Interferon Res (1993) 0.77
A rapid in vitro cytotoxicity assay for the detection of tumor necrosis factor on human BT-20 cells. J Immunother (1991) (1991) 0.76
Current issues in clinical engineering and biomedical technology certification. Biomed Instrum Technol (1990) 0.75
BMETs: the state of the profession. Interview by Michael Miller. Biomed Instrum Technol (1991) 0.75
Developing a strategy for managing the hospital's growing technology. J Clin Eng (1983) 0.75